Clinical Features and Treatment of Systemic Lupus Erythematosus (SLE) in Pediatric Patients

Epidemiology and Presentation

Approximately 20% of SLE cases are diagnosed before 18 years of age, with genetic components being more common in childhood-onset SLE 1, 2
Pediatric SLE typically presents with more severe disease compared to adult-onset SLE 1

Initial workup should include ANA, anti-dsDNA, complement levels, CBC, renal function, and urinalysis 3
Positive ANA warrants further evaluation with additional immunological tests including anti-Sm antibodies, anti-Ro/SSA, anti-La/SSB, and antiphospholipid antibodies 3
Regular monitoring is essential as kidney involvement can remain asymptomatic for significant periods 4
Higher index of suspicion should be maintained for patients of Asian, African/Caribbean, and Hispanic descent 4

The American College of Rheumatology recommends hydroxychloroquine as the cornerstone of treatment for most pediatric SLE patients 3
All SLE patients should receive hydroxychloroquine unless contraindicated 3
Induction therapy typically includes glucocorticoids with either mycophenolic acid (MPAA) or cyclophosphamide 1, 2
Maintenance therapy commonly involves MPAA 1, 2

Pediatric SLE patients should be co-managed by pediatric nephrologists and rheumatologists with expertise in lupus 1, 2
Additional support from clinical psychologists, psychiatrists, or social workers is often beneficial 1, 2

Long-term data shows survival rates without advanced CKD, kidney failure, or death of 94.2%, 92.7%, and 83.2% at 5, 10, and 20 years, respectively 1, 2

Due to high risk of pneumococcal infection, immunization is recommended for pediatric SLE patients 5
Ideally, vaccinations should be administered prior to initiation of immunosuppressive therapy 5